Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1080

Icatolimab

Home » Icatolimab

Background of Icatolimab

Icatolimab (TAB004/JS004) is a humanized recombinant IgG4 monoclonal antibody against B- and T-lymphocyte attenuation factor (BTLA). In vitro and in vivo studies have shown TAB004 or JS004 can promote antigen specific T cell proliferation and effector function, reduce tumor burden and improve survival in human BTLA knock-in tumor models.

Specifications

Catalog Number:
KB-1080
Antibody Name:
Icatolimab
Isotype:
Human IgG4-S228P, kappa
FC Muations:
S228P
Target:
BTLA
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA | FACS
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Bosch F, Dalla-Favera R (2019) Chronic lymphocytic leukaemia: from genetics to treatment. Nat Rev Clin Oncol 16:684–701.
  2. Burger JA, O’Brien S (2018) Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol 15:510–527.